A5102802603- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Helicobacter pylori-related gastroenterology studies
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- Wnt/β-catenin signaling in development and cancer
- Selenium in Biological Systems
- Cancer, Hypoxia, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Metastasis and carcinoma case studies
- Gallbladder and Bile Duct Disorders
- Cancer Cells and Metastasis
- Advanced MRI Techniques and Applications
- Cancer-related gene regulation
- Mathematical Control Systems and Analysis
- Urinary and Genital Oncology Studies
Henan Cancer Hospital
2020-2025
Zhengzhou University
2020-2025
Peking University
2022
Henan Tianguan Group (China)
2020
Renji Hospital
2020
Qilu Hospital of Shandong University
2014-2016
Programmed death receptor-1 (PD-1) blockade shows little benefit in patients with microsatellite-stable colorectal cancer (MSS-CRC). Fruquintinib is a China-made anti-angiogenic drug which approved for the third line therapy mCRC. This study investigates effect of combination fruquintinib and PD-1 on MSS-CRC its relative mechanisms.The mouse allograft tumor models that represent MSS microsatellite instability (MSI) CRC were established using murine CT26 MC38 colon cells, respectively, to...
Multidrug resistance (MDR) is the main cause of clinical treatment failure and poor prognosis in cancer. Targeting P-glycoprotein (P-gp) has been regarded as an effective strategy to overcome MDR. In this work, we reported our preclinical studies triazolo[1,5-a]pyrimidine-based compound WS-716 a highly potent, specific, orally active P-gp inhibitor. Through direct binding P-gp, inhibited efflux function specifically reversed P-gp-mediated MDR paclitaxel (PTX) multiple resistant cell lines,...
Background: Diffuse Gastric Cancer (DGC) is a highly aggressive form of gastric cancer with poor prognosis. Oxaliplatin (OX) one the first-line chemotherapeutic agents for treatment cancer. However, some patients DGC do not benefit from OX therapy. Resibufogenin (RBF), main active components Chinese medicine Huachansu, has demonstrated significant anti-cancer effects. Nevertheless, potential RBF to enhance sensitivity in and its underlying mechanisms have been reported. Objective: The aim...
Novel ADC drugs provide a new therapeutic strategy for gastric cancer.The present study aimed to analyze the clinical efficacy and drug toxicities of disitamab vedotin (RC48) plus immune checkpoint inhibitors(ICIs) RC48 as third-line therapies beyond advanced metastatic cancer patients.This was an observational multicenter real-world study.From August 2021 January 2022,patients with HER2-positive or HER2-low failed from two more lines prior therapy were enrolled treated ICIs RC48. In this...
Background: For patients with human epidermal growth factor receptor-2 (HER2)-positive advanced or metastatic gastric cancer who have progressed on first-line trastuzumab therapy, the clinical value of continuous use beyond progression (TBP) is controversial. Objectives: The present study was conducted to evaluate efficacy and explore new treatment strategies TBP for trastuzumab-resistant HER2-positive in era immunotherapy. Design: Retrospective analysis. Methods: Patients failed based...
Cancer-associated fibroblasts (CAFs) has been recognized as one cause of tumor resistance to immune checkpoint blockade therapy, but the underlying mechanisms still remain elusive. In present study, a bone marrow-derived CAF (BMF) -rich model is successfully established by subcutaneously mixed inoculation BMFs and cells into mice BMF-mixed xenografts are demonstrated be resistant anti-PD-L1 antibody immunotherapy compared mere xenografts. vitro assays via co-culture system indicate that...
The antitumor activity of nivolumab plus regorafenib in colorectal cancer from a phase Ib REGONIVO study is encouraging. present was conducted to evaluate the efficacy and safety or fruquintinib sintilimab as third-line above therapy patients with microsatellite stable (MSS) metastatic cancer.Patients MSS who have failed prior treatment received January 2019 December 2020 were prospectively analyzed based on real-world clinical practice. primary end point progression free survival (PFS)....
Abstract Utidelone (UTD1), a novel microtubule stabilizing agent, is an epothilone B analogue which was produced by genetic engineering. UTD1 has exhibited broad antitumor activity in multiple solid tumors. However, its and mechanism colorectal cancer (CRC) remain to be studied. In this study, dramatically inhibited CRC cell proliferation (with 0.38 µg/ml, 0.77 µg/ml IC50 RKO HCT116, respectively) vitro. Immunofluorescence staining showed that induced the formation of bundling asters cells....
This is the first clinical study that wants to investigate treatment patterns, outcomes, and prognostic factors of regorafenib plus PD-1 inhibitors therapy in Chinese elderly patients with advanced colorectal cancer.
Unresectable advanced or recurrent gastric cancer patients have a poor prognosis. PD-1 monotherapy regimen and combined chemotherapy become the standard third- first-line treatment for cancer, respectively. However, status of immune checkpoint inhibitors in second-line has not been established. The combination anti-PD-1 antibody demonstrated to synergistic effect. In this study, we aimed evaluate efficacy safety sintilimab with nab-paclitaxel (GC)/gastroesophageal junction (GEJ) patients.We...
Background. The morbidity and mortality of gastric cancer are high in China. There challenges to develop precise individualized drug regimens for patients with after a standard treatment. Choosing the most appropriate anticancer patient developing resistance is very important improve patient’s prognosis. MiniPDX has been widely used as new reliable preclinical research model predict sensitivity drugs. Methods. OncoVee® system developed by Shanghai LIDE Biotech Co., Ltd. was establish models...
Kremen2 (Krm2) plays an important role in embryonic development, bone formation, and tumorigenesis as a crucial regulator of classical Wnt/ β -catenin signaling pathway. However, the Krm2 gastric cancer is not clear. The aim this study was to explore regulatory metastasis cancer. It demonstrated that, compared para-cancerous tissues, significantly up-regulated tissues positively correlated with pathological grade patients. Given that abundantly expressed most tested cell lines, knockdown...
Abstract Introduction The present study aims to evaluate the efficacy and safety of apatinib monotherapy or combination therapy for patients with advanced recurrent biliary tract cancer (BTC). Methods Twenty-eight BTC who progressed after prior systemic therapies treated from January 2017 June 2019 were enrolled in this retrospective observational study. primary end point was progression free survival (PFS). Secondary points included overall (OS), objective response rate (ORR), disease...
Gliomas are the most common type of primary brain tumor. Radiation therapy (RT) is adjuvant treatment to eliminate residual tumor tissue after surgery. However, current RT guided by conventional imaging unsatisfactory. A fundamental question whether it possible further enhance effectiveness and efficiency based on individual radiosensitivity. In this research, probe correlation between radiosensitivity metabolite characteristics glioma cells in vitro, a perchloric acid (PCA) extracting...
Murine bone marrow-derived myofibroblasts (BMFs) have previously been shown to promote gastric cancer growth. However, whether BMFs cell metastasis remains largely unknown.Wound healing assay, Transwell invasion and migration assay 3D organotypic co-culture systems were conducted study the effects of on cells ability stem cell-like (CSC-LCs) induced by BMFs. We employed two animal model role in vivo metastatic BMF-induced CSC-LCs. A human tissue microarray TCGA database analysed relationship...
PD-L1 and HER-2 are routine biomarkers for gastric cancer (GC). However, little research has been done to investigate the correlation among PD-L1, HER-2, immune microenvironment, clinical features in GC.Between January 2013 May 2020, a total of 120 GC patients treated with chemotherapy were admitted Henan Tumor Hospital. We retrospectively identified level before abstracted clinicopathologic treatment outcomes. Univariate multivariate survival analyses performed assess relationship between...
Based on increasing research evidence, hepatocellular carcinoma (HCC) is heterogeneous, and genetic profiling has led to the identification of multiple subtypes this disease. To advance our knowledge ability use individualized medicine in treatment HCC, it essential perform a complete methodical characterization various molecular subtypes. The canonical Wnt/β-catenin pathway an evolutionarily conserved complicated signaling mechanism that plays role carcinogenesis progression HCC. In study,...
The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy still the main first-line treatment for carcinoma, while immunotherapy can be used as a option people who cannot tolerate platinum. Immunotherapy preferred in second-line bladder carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) PD-L1 (Ddurvalumab avelumab) have not been approved cancer China. We describe patient experienced disease progression after gemcitabine...